Caffeine and cognitive decline in elderly women at high vascular risk.: Caffeine and cognition in high-risk women by Vercambre, Marie-Noël et al.
Caffeine and cognitive decline in elderly women at high
vascular risk.
Marie-Noe¨l Vercambre, Claudine Berr, Karen Ritchie, Jae Kang
To cite this version:
Marie-Noe¨l Vercambre, Claudine Berr, Karen Ritchie, Jae Kang. Caffeine and cognitive decline
in elderly women at high vascular risk.: Caffeine and cognition in high-risk women. Journal of
Alzheimer’s Disease, IOS Press, 2013, 35 (2), pp.413-21. <10.3233/JAD-122371>. <inserm-
00833357>
HAL Id: inserm-00833357
http://www.hal.inserm.fr/inserm-00833357
Submitted on 12 Jun 2013
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.
 1 
Caffeine and cognitive decline in elderly women at high vascular risk 
 
Marie-Noël Vercambre
1*
, PhD (mvercambre@mgen.fr) 
Claudine Berr
2,3
, MD PhD  (claudine.berr@inserm.fr) 
Karen Ritchie
2,3
, PhD   (karen.ritchie@inserm.fr) 
Jae H. Kang
4
, ScD   (nhjhk@channing.harvard.edu) 
 
1
 From the MGEN Foundation for Public Health, Paris, France 
2 
From Inserm, U1061, Montpellier, France 
3
 From the University of Montpellier 1, Montpellier, France 
4
 From the Channing Division of Network Medicine, Department of Medicine, Brigham and 
Women’s Hospital, Harvard Medical School, Boston, MA 
 
 
Suggested running title: Caffeine and cognition in high-risk women 
 
*Corresponding author: Marie-Noël Vercambre 
Phone: +33 (0)1 40 47 20 43; Fax: +33 (0)1 40 47 21 91. 
MGEN Foundation for Public Health, 3 square Max-Hymans, 75748 Paris Cedex 15 
 
 
 
 
 2 
ABSTRACT 
Background: Persons with vascular disorders are at higher risk of cognitive decline. 
Objective: To determine whether caffeine may be associated with cognitive decline reduction 
in elderly at high vascular risk. 
Methods: We included 2475 women aged 65+ years in the Women’s Antioxidant 
Cardiovascular Study, a randomized trial of antioxidants and B vitamins for cardiovascular 
disease secondary prevention. We ascertained regular caffeine intake at baseline (1995-1996) 
using a validated 116 item-food frequency questionnaire. From 1998-2000 to 2005-2006, we 
administered four telephone cognitive assessments at two-year intervals evaluating global 
cognition, verbal memory and category fluency. The primary outcome was the change in 
global cognitive score, which was the average of the z-scores of all tests. We used generalized 
linear models for repeated measures that were adjusted for various sociodemographic, health 
and lifestyle factors to evaluate the difference in cognitive decline rates across quintiles of 
caffeine intake. 
 Results: We observed significantly slower rates of cognitive decline with increasing caffeine 
intake (p-trend=0.02). The rate difference between the highest and lowest quintiles of usual 
caffeine intake (> 371 versus < 30 mg/day) was equivalent to that observed between those 
who were 7 years apart in age (p=0.006). Consumption of caffeinated coffee was significantly 
related to slower cognitive decline (p-trend=0.05), but not other caffeinated products (e.g., 
decaf, tea, cola, chocolate). We conducted interaction analyses and observed stronger 
associations in women assigned to vitamin B supplementation (p-interaction = 0.02). 
Conclusions: Caffeine intake was related to moderately better cognitive maintenance over 5 
years in older women with vascular disorders. 
 
Keywords: Cognition; Aging; Caffeine; Cohort studies; Risk factors; Epidemiology 
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INTRODUCTION 
Caffeine has well known acute effects on alertness, mood, attention and energy [1]; caffeine 
may also have more long-term positive effects [2], including maintaining cognitive function 
into old age [3-6]. However, data are still lacking on whether caffeine may show beneficial 
associations with cognitive function among individuals suffering from pathologies already 
known to accelerate cognitive decline, notably cardiovascular disease [7]. In western 
countries, coffee is the major dietary source of caffeine in adults, with the highest 
consumption in adults over 30 years of age [8, 9], a point in the life-span at which rates of 
cardiovascular disorders with their associated risk of later-life cognitive impairment [10] also 
increase rapidly. Given the growing number of studies suggesting caffeine may have a 
vascular protective effect [11-13] and the lack of major adverse outcomes associated with 
caffeine consumption among groups at high cardiovascular risk [14], caffeine intake/coffee 
consumption is a promising exposure to evaluate in persons at high risk of cognitive 
impairment due to vascular risk factors. Thus, we examined the association between caffeine 
intake and cognitive decline over 5 years among 2475 elderly participants of the Women’s 
Antioxidant Cardiovascular Study (WACS), a cohort of women with vascular disease or 
coronary risk factors. Our hypothesis was that moderate to high caffeine intake would be 
associated with greater cognitive stability in a dose-dependent manner. 
 
MATERIALS AND METHODS 
The WACS began in 1995-1996 (baseline) and included 8171 women, as a 2x2x2 randomized 
placebo-controlled trial of vitamin E, vitamin C, and beta-carotene supplementation for the 
secondary prevention of cardiovascular disease (CVD) [15]. Eligible participants were female 
health professionals, aged ≥ 40 years, with prevalent CVD or ≥ 3 coronary risk factors (i.e., 
parental history of premature myocardial infarction (MI), diabetes, hypertension, 
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hyperlipidemia, and body mass index ≥ 30 kg/m2). Prevalent CVD included MI, stroke, 
revascularization procedures, symptomatic angina pectoris, or transient cerebral ischemia. In 
1998, a fourth arm for B vitamin supplementation (combined folic acid, vitamin B6, and 
vitamin B12) was added among 5442 women [16]. Until the scheduled end in 2005, 
participants completed annual questionnaires on compliance, side effects, health, lifestyle and 
clinical endpoints. None of the supplements were found to reduce cardiovascular disease 
recurrence [15, 16] or influence cognitive decline [17, 18]. 
 
Cognitive sub-cohort 
From 1998-2000, we assessed cognitive function through telephone interviews among 
participants aged ≥ 65 years. Of the 3170 eligible women, 190 were unreachable, 156 
declined participation, and 2824 (95% of contacted women) completed the initial telephone 
cognitive assessment. These women received three further follow-up assessments at two-year 
intervals until 2005; 93% completed at least two cognitive assessments, and 81% completed 
at least three among four. For the fourth assessment, 24% of participants were not contacted 
as only a short interval had passed between their third interview and the end of the trial. The 
mean time from the initial to the last cognitive assessment was 5.4 years (range 4.1–6.1 
years). The cognitive WACS sub-study was approved by the institutional review board of the 
Brigham and Women’s Hospital, Boston, MA. 
 
Cognitive Assessment 
The telephone interview consisted of five cognitive tests, whose validity has already been 
described in detail previously [19, 20]. Global cognition was evaluated with the Telephone 
Interview of Cognitive Status (TICS) [21], a telephone adaptation of the Mini-Mental State 
Examination (range 0 to 41 points). Verbal memory was assessed with the TICS 10-word list 
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(immediate and delayed recall) and the East Boston Memory Test (immediate and delayed 
recall) [22]. A test of category fluency [23], in which women were asked to name as many 
animals as possible in one minute, was also administered. 
Our primary outcome was the annual rate of change from the initial through the last 
assessment in a global composite score, computed as the mean of the z-scores from all 
cognitive tests (“global cognitive score”). As secondary outcomes, we considered the changes 
in TICS score, verbal memory composite score (mean of the z-scores from the immediate and 
delayed recalls of both TICS-10 word list and the East Boston Memory Test: “verbal memory 
score”), and category fluency score. Verbal memory is among the best predictors of 
Alzheimer disease [24]. Category fluency task activate a complex neural network 
encompassing frontal, parietal and angular regions, as well as the superior temporal gyri and 
the cerebellum [25]. This task is highly sensitive to vascular disorders in many cortical and 
sub-cortical areas of the brain, notably frontal-subcortical connections [26]. 
To derive the composite scores for participants who did not complete all tests (only 0.5% of 
the interviewed persons), we used the means of the z-scores from the available relevant tests. 
 
Caffeine intake 
The Willett semi-quantitative food frequency questionnaire was administered at WACS 
baseline. This dietary questionnaire, which has been extensively validated [27], asked about 
usual consumption during the past year of 116 food/beverage items, including “coffee with 
caffeine”, “decaffeinated coffee”, “tea, not herbal tea”, “Coke, Pepsi, or other cola with 
sugar”, “low-calorie cola, e.g, diet coke with caffeine” and “chocolate (e.g. Hershey’s, M & 
M’s)”. Respondents had to choose among nine possible response categories with a specified 
portion size (1 glass, bottle or can; 1 cup; 1 bar or packet; etc.). The reports of coffee 
consumption has been found to show high validity in a study with similar participants [28]. 
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For each food/beverage item, the reported amount consumed daily (calculated taking into 
account the consumption frequency together with the portion size) was multiplied by its 
caffeine content from the US Department of Agriculture National Nutrient Database for 
Standard Reference (http://www.ars.usda.gov/nutrientdata). Usual daily caffeine intake was 
computed as a sum across all food/beverage sources. Caffeine intake was first energy-
adjusted using the residual method [29] and then categorized into quintiles. 
We also considered the usual consumption of the main contributors of caffeine: caffeinated 
coffee, decaffeinated coffee, caffeinated cola, caffeinated diet cola, tea, and chocolate. 
The mean time from the food frequency questionnaire to the initial cognitive assessment was 
3.5 years (range 3.1-4.7 years). This lag period likely has some benefits. First, because diet 
was assessed at somewhat younger ages, the possibility of reverse causation (i.e. changes in 
diet due to underlying cognitive status leading to spurious associations) is minimized. Second, 
biologically, diet at more remote timepoints is probably more relevant to brain health than 
more immediate diet, as cognitive decline develops over a long period of time [24]. To further 
evaluate caffeine intake that represents stable intake over the long-run and to assess the 
robustness of our results to recent changes in diet, we conducted subgroup analyses only 
among women who reported at WACS baseline that their diet changed very little in the past 
five years. 
For this study on diet and cognitive decline, 349 participants among the 2824 with initial 
cognitive assessment were excluded because of incomplete dietary information. Excluded 
women showed slightly lower cognitive scores than included women. There was no 
difference in caffeine intake between eligible women participating and not participating in the 
cognitive subcohort. In the end, the analysis sample for the present study included 2475 
women. 
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Covariates 
We obtained information on numerous potential confounders including sociodemographic 
status, medical conditions, medications and lifestyle factors plausibly linked with both 
cognitive decline and dietary habits. Basic models included age at initial cognitive 
assessment, education and energy from diet. In full multivariable models, we further adjusted 
for the WACS randomization assignments, as well as lifestyle and health variables (described 
in the footnote of Table 2). In secondary analyses, we further adjusted for incident vascular 
events during follow-up. 
 
Statistical Analysis 
We used general linear models for repeated measures with random intercepts and slopes to 
estimate the association of caffeine intake level with the annual rate of cognitive change. The 
longitudinal correlation in scores within subject was incorporated into the models using an 
unstructured covariance matrix. To help interpret the mean differences in annual rate of 
cognitive decline, we compared the effect estimate we found for caffeine and cognitive 
decline to that for age and cognitive decline, thus using the effect of age on cognitive decline 
as a “benchmark” for interpreting the mean differences in rates. 
We tested for linear trends across quintiles of caffeine intake by assigning the median intake 
to each of the five categories as a continuous ordinal variable. We used Wald tests for 
statistical testing. All models were fitted by maximum likelihood method using the SAS 
software (SAS release 9.1, SAS Institute Inc., Cary, NC). 
Considering the possibility that caffeine intake patterns or associations with cognitive decline 
may differ according to age, hypertension, diabetes, overall cardiovascular profile at baseline 
(prevalent CVD vs. vascular risk factors only), alcohol, smoking status, and trial assignment, 
we evaluated the interaction terms between caffeine intake and each of these factors and 
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conducted stratified analyses by potential effect modifiers (p-interaction <0.10). We also 
conducted analyses only among women with intact cognitive function at initial assessment (in 
the top 90
th
 percentile of global cognitive score). 
 
RESULTS 
The mean score in our population at first cognitive assessment was 34.3 on TICS and 16.4 on 
category fluency test. 
Higher caffeine intake was associated with lower age, greater alcohol consumption, lower 
level of physical activity and current smoking (Table 1). Concerning cardiovascular 
conditions/risk factors, higher caffeine intake was related to modestly lower prevalence of a 
history of hypertension and hyperlipidemia, but was not associated with the prevalence of a 
history of clinical MI, stroke, revascularization surgery, angina, transient ischemic attack, or 
diabetes. 
 
Caffeine intake and cognitive change 
In the multivariable-adjusted models, higher caffeine intake was related to rates of decline 
that were significantly slower in the global cognitive score (p-trend=0.02) and verbal memory 
score (p-trend=0.05) (Table 2). Higher caffeine intake was also inversely but not significantly 
associated with decline in the TICS (p-trend=0.07) and category fluency score (p-trend=0.08). 
In particular, women in the highest quintile of daily caffeine intake had significantly slower 
global cognitive decline than those in the bottom quintile (p<0.01); the caffeine in the highest 
quintile is equivalent to the amount of caffeine in approximately 4 cups of coffee (>371 
mg/day). Dividing the effect estimate we found for caffeine and cognitive decline (0.028 
standard unit/year slower rate of decline between the top and first quintile) by that for age and 
cognitive decline (0.004 standard unit/year slower rate of decline for every year of being 
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younger), we observed that the mean difference in rates of cognitive change between the fifth 
and first quintiles of caffeine intake was equivalent to the mean differences found for women 
7 years apart in age. Results were not substantially altered when we controlled for incident 
major cardiovascular events during follow-up. 
In multivariable models of cognitive change, we also evaluated the consumption of the main 
contributors to caffeine intake as exposure variables (data not shown in table). We detected a 
significant association between increasing caffeinated coffee consumption and slower 
cognitive decline (the difference in rate for global score change for ≥ 4 cups / day vs. none 
was 0.02 (95% Confidence Intervals (CI) = 0.00, 0.05); p-trend=0.05) but we observed no 
associations with decaffeinated coffee (the difference in rate for ≥ 2 cups/day vs. none was -
0.01 (95% CI = -0.03, 0.01); p-trend=0.09). Similarly no associations were observed with the 
other caffeinated products (tea, cola with caffeine, diet cola with caffeine, chocolate). 
 
Secondary analyses 
Among the subset of 840 women who declared a stable diet over the previous 5 years at 
baseline, we observed similar (and somewhat stronger) associations between caffeine and 
cognitive maintenance (Table 3). 
Models limited to women in the top 90
th
 percentile of global score at first cognitive interview 
(i.e., with preserved cognitive function) yielded similar significant results as the primary 
analyses (Table 3). 
We observed no significant interaction with age, alcohol, smoking status, overall 
cardiovascular profile at baseline (prevalent CVD vs. vascular risk factors only), diabetes, 
hypertension or assignment to vitamin C, E or beta-carotene. However, when we examined 
whether the association differed by trial assignment to vitamin B (active [n=890] vs. not 
participating [n=700] or placebo [n=885]), we found that the protective association between 
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higher caffeine intake and cognitive decline was more pronounced among those assigned to 
vitamin B supplementation (p for interaction=0.02) (Table 4). 
 
DISCUSSION 
In our prospective study of over 2400 women with vascular conditions, those with higher 
caffeine intake (approximately 4 cups of coffee per day) showed significantly less 5-year 
decline in global cognitive functioning and in verbal memory compared to low- or non-
consumers of caffeinated products. 
Our results are consistent with previous studies [3-6, 30], and support the notion of a long-
term protective effect of caffeine in cognitive decline. A unique contribution of our study has 
been to demonstrate that this protective effect is also evident in women with CVD or 
cardiovascular risk factors, who are at increased risk of cognitive impairment. Also, in this 
population of women whose baseline caffeine intake was not clearly related to cardiovascular 
health status, we observed an association between caffeine and cognitive maintenance, which 
was significant even when cardiovascular factors were controlled for, suggesting a direct 
neuroprotective effect of caffeine, independent of its putative indirect effect on cognition 
through cardiovascular risk modulation. The causal relationship is further supported by our 
observation of a dose-effect and well-known biological effects of caffeine on brain function 
[31], including modulation of white matter lesions and/or microvascular ischemic lesions 
[32]. A potential mechanism for the long-term neuroprotective effect of caffeine may involve 
blockade of adenosine A2A receptors [1], which may attenuate damage caused by beta-
amyloid, the toxic peptide that accumulates in the brain of patients with Alzheimer disease 
(AD) [33]. Indeed, both acute or long-term caffeine administration were shown to reduce 
brain amyloid-beta levels in AD transgenic mice [34, 35] and memory restoration and reversal 
of AD pathology in mice with preexisting beta-amyloid burden [36]. Another neuroprotective 
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mechanism for caffeine would involve improving insulin sensitivity [37] and reducing the risk 
of diabetes [11], which is a strong risk factor for cognitive decline; this pathway would be 
particularly more relevant in populations with CVD or cardiovascular risk factors such as 
ours. More generally, protective effects of caffeine in cognitive aging could also be mediated 
through benefits on psychological factors, as caffeine may improve depressive symptoms 
[38], which, in turn, may protect against decline in cognitive functioning [39]. 
We further observed that the protective association with higher caffeine intake was stronger 
among women who were supplemented with B vitamins (folic acid, B6 and B12). Although 
this may be a chance finding, this result has some biological plausibility. An adverse effect of 
high coffee intake is the elevation of homocysteine [40], which is neurotoxic [41], and it has 
previously been reported that the cytogenetic damage induced by folate deficiency in mice 
was enhanced by large amounts of caffeine [42]. It is possible that in those with vitamin B 
supplementation, higher caffeine intake would not cause neurotoxic elevations in 
homocysteine, while still exerting other neuroprotective effects. This finding warrants further 
investigation. 
Major strengths of the study included its large sample size, longitudinal design, the use of a 
validated cognitive test battery and the opportunity to adjust for several potential confounders 
such as smoking, physical activity and depression. Also, we implemented generalized linear 
models for repeated measures that took into account the within-person intra-correlation of 
assessments and that allows for data with incomplete follow-up, thus limiting attrition bias. 
Furthermore, the use of repeated cognitive assessment reduces the measurement error in the 
longitudinal analyses. 
Regarding the limitations of this study, caffeinated product consumption was assessed using a 
self-administered questionnaire, which, although validated, fails to differentiate coffee bean 
type or method of preparation. Also, self-administered food frequency questionnaire could 
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have induced some differential misclassification. Caffeine intake might have been under-
estimated in cognitively impaired persons who also had more frequent missing information 
and might be more likely to experiment decline. However, results were unchanged in the 
stratified analysis among persons with preserved cognitive function at initial cognitive 
assessment (top 90
th
 percentile of global score). Also, the intake may not reflect long-term use 
as it was based on just the baseline assessment. However, recent data suggest that caffeinated 
beverage drinking habits are relatively stable over time [4], even in those with CVD events 
[14]. Moreover, our results were similar (and somewhat stronger) among women reporting a 
stable diet over the past 5 years. Thus, our results support the idea that for maintenance of 
cognitive health into old age, habitual long-term caffeine intake may be of importance. 
Although we were able to adjust for a large number of covariates, residual confounding 
remains a possibility (e.g., unmeasured beneficial lifestyle or social factors associated with 
coffee drinking). Because our study included only women, we are not able to generalize our 
findings to men. Results from previous studies suggest that women may be more sensitive 
than men to the positive effects of caffeine against both cardiovascular risk [12] and cognitive 
aging [31]. This differential effect of caffeine by sex should be examined in further studies. 
Finally, among the various constituents of coffee, we were able to directly measure the intake 
of caffeine; however, studies have shown that other constituents in coffee (e.g. polyphenols) 
may also have direct neuroprotective effects [43]. In this study, we were unable to evaluate 
other non-caffeine components in coffee and their relation to cognition. Although the results 
of our analysis (associations with caffeine and an associations with caffeinated but not de-
caffeinated coffee consumption) are consistent with putative caffeine effects, further studies, 
including randomized clinical trials of caffeine, would be needed to isolate the effects of 
caffeine versus the effect of other coffee components on cognition. 
 
 13 
CONCLUSION 
In our cohort of over 2400 elderly women with vascular conditions, higher caffeine intake 
was associated with lesser cognitive decline over a 5-year period. Given the global population 
aging and related increasing prevalence of both cardiovascular and cognitive pathologies, and 
because the modifiable lifestyle habit of caffeinated products consumption is particularly 
common and socially well-integrated, our results could have major public health implications. 
However, as a psychoactive stimulant molecule with potentially detrimental effects associated 
with excessive intake (withdrawal, sleep deprivation, etc), further confirmatory studies, 
including short-term clinical trials, evaluating different dosages and timing of caffeine intake 
on cognition are warranted. 
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Table 1. Characteristics
a
 of the WACS cognitive cohort participants by quintile of caffeine 
intake (n=2475) 
 
a 
Values are means (standard deviation) or percentages and are standardized to the age 
distribution of the study population (except for the age variable); those with missing 
information were not included for the tabulation 
 Quintile of caffeine intake  
 Q1 Q2 Q3 Q4 Q5 p value
c
 
Age at initial cognitive assessment (y) 72.9(4.6) 72.6(4.2) 72.4(4.2) 72.3(4.1) 71.9(3.6) *** 
Master’s or a doctoral degree (%) 12 10 12 12 10 ns 
Married (%) 60 62 61 58 59 ns 
Alcohol intake (g/d) 2.8(6.9) 3.4(7.8) 3.7(8.4) 5.1(10.4) 3.9(7.9) *** 
Physical activity
b
 (kcal/wk) 1053(1377) 960(1220) 891(1340) 817(1011) 830(975) * 
Use of multivitamin supplements (%) 32 30 29 31 26 ns 
Current smoker (%) 5 6 7 13 18 *** 
Body Mass Index (kg/m
2
) 28.9(5.6) 28.7(5.5) 28.9(6.0) 28.7(5.7) 27.9(5.4) ns 
History of depression (%) 13 17 16 16 14 ns 
History of myocardial infarction (%) 25 19 20 20 20 ns 
History of stroke (%) 9 7 10 9 7 ns 
History of revascularization surgery (%) 21 20 19 21 22 ns 
History of angina (%) 43 50 46 43 44 ns 
History of transient ischemic attack (%) 15 16 16 16 15 ns 
History of diabetes (%) 21 18 17 18 14 ns 
History of hypertension (%) 80 81 78 75 74 * 
History of hyperlipidemia (%) 77 79 74 69 75 ** 
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b
 Weekly calories expended from exercise and climbing the stairs 
c
 From chi-squared tests or analysis of variance depending on the type of variable (categorical 
or numeric): ns = non-significant, * = p<0.05, ** = p<0.01, *** = p<0.001 
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Table 2. Adjusted mean differences (95% confidence intervals) in annual rates of cognitive change by quintiles of caffeine intake, WACS 
cognitive cohort (n=2475) 
 Quintile of caffeine intake  
 Q1 Q2 Q3 Q4 Q5  
Median intake (mg/day) 10 57 152 296 495  
Range <30 30-111 112-203 204-371 >371 p Trend 
Global cognitive score
a
       
Basic-adjusted model
b 
0 (Reference) 0.01 (-0.01, 0.03) 0.01 (-0.01, 0.03) 0.00 (-0.02, 0.02) 0.02 (0.00, 0.04) 0.066 
Multivariable-adjusted model
c 
0 (Reference) 0.01 (-0.01, 0.03) 0.02 (0.00, 0.04) 0.00 (-0.02, 0.02) 0.03 (0.01, 0.05) 0.020 
TICS       
Basic-adjusted model
b 
0 (Reference) -0.02 (-0.12, 0.07) -0.01 (-0.10, 0.09) -0.02 (-0.12, 0.07) 0.06 (-0.03, 0.15) 0.151 
Multivariable-adjusted model
c 
0 (Reference) 0.00 (-0.09, 0.10) 0.03 (-0.07, 0.12) 0.00 (-0.09, 0.09) 0.09 (-0.01, 0.18) 0.074 
Verbal memory
a
       
Basic-adjusted model
b 
0 (Reference) 0.00 (-0.02, 0.02) 0.01 (-0.01, 0.03) 0.00 (-0.02, 0.02) 0.02 (0.00, 0.04) 0.110 
Multivariable-adjusted model
c 
0 (Reference) 0.00 (-0.02, 0.03) 0.01 (-0.01, 0.04) 0.00 (-0.02, 0.03) 0.02 (0.00, 0.05) 0.048 
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Category fluency       
Basic-adjusted model
b 
0 (Reference) 0.06 (-0.07, 0.19) 0.06 (-0.07, 0.19) 0.07 (-0.07, 0.20) 0.12 (-0.01, 0.25) 0.115 
Multivariable-adjusted model
c 
0 (Reference) 0.04 (-0.09, 0.18) 0.05 (-0.08, 0.18) 0.06 (-0.07, 0.20) 0.13 (-0.01, 0.26) 0.077 
TICS: Telephone Interview of Cognitive Status 
a 
Global cognitive score is a composite score of the z-scores of the TICS, immediate and delayed recalls of the East Boston Memory Test, 
category fluency, and delayed recall of the TICS 10-word list; verbal memory score is a composite score of the z-scores of the immediate and 
delayed recalls of both the TICS 10-word and the East Boston Memory Test 
b
 Adjusted for age (years), education (licensed practical nurse, vocational nurse or associate’s degree; registered nurse degree or bachelor’s 
degree; master’s or doctoral degree) and energy from diet (tertiles) 
c
 Further adjusted for marital status (married, divorced, widowed, single), alcohol intake (abstainer, 0.1-0.9g/day, ≥10g/day), physical activity 
(quartiles of weekly calories expended from exercise and climbing the stairs), use of multivitamin supplements (no, yes), smoking status (never, 
past, current), body mass index (quartiles), postmenopausal hormone therapy use (never, past, current), aspirin use exceeding 10 days in the 
previous month (no, yes), non-steroidal anti-inflammatory drug use exceeding 10 days in the previous month (no, yes), history of depression (no, 
yes), cardiovascular profile at baseline (myocardial infarction, stroke, revascularization procedures, symptomatic angina pectoris, transient 
cerebral ischemia, no clinical disease), diabetes (no, yes), hypertension (no, yes on pharmaceutical treatment, yes without pharmaceutical 
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treatment), hyperlipidemia (no, yes on pharmaceutical treatment, yes without pharmaceutical treatment), dietary intakes of vitamin C (tertiles), 
vitamin E (tertiles), carotene (tertiles), vitamin B6 (tertiles), vitamin B12 (tertiles) and folates (tertiles), and randomization assignment for 
vitamin E (placebo, active), vitamin C (placebo, active), beta-carotene (placebo, active), and folate (not assigned, placebo, active)
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Table 3. Adjusted
a
 mean differences (95% confidence intervals) in annual rates of cognitive change by quintiles of caffeine intake in two 
different strata, WACS cognitive cohort 
 Quintile of caffeine intake  
 Q1 Q2 Q3 Q4 Q5 p Trend 
Among the subset of women who reported a stable diet at baseline (no major change in diet over the prior 5 years) (N=840) 
Global cognitive score
b 
0 (reference) 0.03 (-0.01, 0.06) 0.05 (0.01, 0.08) 0.03 (-0.01, 0.06) 0.06 (0.03, 0.10) 0.004 
TICS 0 (reference) 0.04 (-0.13, 0.21) 0.06 (-0.11, 0.23) 0.08 (-0.10, 0.25) 0.20 (0.02, 0.37) 0.022 
Verbal memory
b
 0 (reference) 0.02 (-0.02, 0.05) 0.04 (0.01, 0.08) 0.03 (-0.01, 0.06) 0.06 (0.02, 0.09) 0.008 
Category fluency 0 (reference) 0.16 (-0.07, 0.39) 0.22 (-0.01, 0.44) 0.11 (-0.13, 0.35) 0.31 (0.08, 0.55) 0.036 
       
Among the subset of women in the top 90th percentile of global score at first cognitive interview (N=2227) 
Global cognitive score
b 
0 (reference) 0.00 (-0.02, 0.02) 0.01 (-0.01, 0.03) 0.00 (-0.02, 0.02) 0.02 (0.00, 0.04) 0.015 
TICS 0 (reference) -0.02 (-0.11, 0.07) -0.01 (-0.10, 0.07) -0.01 (-0.10, 0.08) 0.08 (-0.01, 0.18) 0.036 
Verbal memory
b
 0 (reference) 0.00 (-0.02, 0.02) 0.01 (-0.01, 0.03) 0.00 (-0.02, 0.03) 0.02 (0.00, 0.04) 0.040 
Category fluency 0 (reference) 0.02 (-0.12, 0.17) 0.02 (-0.12, 0.16) 0.04 (-0.10, 0.18) 0.09 (-0.05, 0.24) 0.177 
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TICS: Telephone Interview of Cognitive Status 
 a 
All models are multivariable-adjusted (covariates listed in footnotes b and c of Table 2) 
b 
Global cognitive score is a composite score of the z-scores of the TICS, immediate and delayed recalls of the East Boston Memory Test, 
category fluency, and delayed recall of the TICS 10-word list; verbal memory score is a composite score of the z-scores of the immediate and 
delayed recalls of both the TICS 10-word and the East Boston Memory Test
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Table 4. Adjusted
a
 mean differences (95% confidence intervals) in annual rates of global cognitive change
b
 by quintiles of caffeine intake, 
stratified by trial assignment to vitamin B supplementation, WACS cognitive cohort 
 Quintile of caffeine intake   
Assignment to vitamin B supplementation Q1 Q2 Q3 Q4 Q5 p Trend p Interaction
a
 
Active (N=890) 0 (reference) 0.02 (-0.01, 0.05) 0.04 (0.00, 0.07) 0.02 (-0.01, 0.05) 0.06 (0.03, 0.09) 0.002  
Not participant
c
 or placebo (N=1585) 0 (reference) -0.01 (-0.03, 0.02) 0.00 (-0.02, 0.03) -0.01 (-0.04, 0.02) 0.01 (-0.02, 0.03) 0.468 0.022 
a 
All models are multivariable-adjusted (covariates listed in footnotes b and c of Table 2) 
b 
Change in the global cognitive score, which is a composite score of the z-scores of the TICS, immediate and delayed recalls of the East Boston 
Memory Test, category fluency, and delayed recall of the TICS 10-word list 
c
 28% of the whole sample did not participate to the Vitamin B supplementation arm of the trial 
 
 
 
 
 
